Zusammenfassung
Der Typ-1-Diabetes entsteht durch eine immunvermittelte Zerstörung der Insulin-produzierenden β-Zellen des Pankreas.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Literatur zu Abschn. 3.1
Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293–300
Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, Martinez EZ, Foss MC, Burt RK, Voltarelli JC (2009) C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301: 1573–1579
Dagan SA, Ziegler AG, Pozzilli PG, Linn T, Schernthaner G, Bonnici F, Elias D, Eren R, Cohen IR, Raz I and Group S (2012) Recent Data from DIA-AID 1, a Global Phase III Clinical Study in Newly Diagnosed Type 1 Diabetes Patients. Diabetes 61 (Suppl 1): 292-OR
Eisenbarth GS (2012) Prediction of Type 1A Diabetes. In: Eisenbarth GS (ed) The natural history of the prediabetic period. Type 1 diabetes: cellular, molecular and clinical immunology. Online edition version 3.0. http://www.ucdenver.edu/academics/colleges/medicalschool/centers/BarbaraDavis/OnlineBooks/Pages/Type1Diabetes.aspx.4 Zugriff 21 Dez 2013
Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR, Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz DA (2013) Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with type 1 diabetes. Biol Blood Marrow Transplant 19: 1126–1129
Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Beck-Neilsen H, Tuomilehto J, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum WA, Williams R, Brophy S, Pozzilli P, Leslie RD; Action LADA consortium (2013) Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 36: 908–913
Knip M, Virtanen SM, Seppä K, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, Hämäläinen AM, Paronen J, Dosch HM, Hakulinen T, Akerblom HK; Finnish TRIGR Study Group (2010) Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 363: 1900–1908
Mallone R, Mannering SI, Brooks-Worrell BM, Durinovic-Belló I, Cilio CM, Wong FS, Schloot NC; T-Cell Workshop Committee, Immunology of Diabetes Society (2011) Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol 163: 33–49
Martin S, Herder C, Schloot NC, Koenig W, Heise T, Heinemann L, Kolb H; DIATOR Study Group (2011) Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One 6: e17554
Neu A, Beyer P, Bürger-Büsing J, Danne T, Etspüler J, Heidtmann B, Holl RW, Karges B, Kiess W, Knerr I, Kordonouri O, Lange K, Lepler R, Marg W, Näke A, Petersen M, Podeswik A, Stachow R, Sengbusch S von, Wagner V, Ziegler R, Holterhus PM (2012) Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. Praxisempfehlungen der Deutschen Diabetes Gesellschaft. Diabetologie 7: S152–S162
Roep BO, Solvason N, Gottlieb PA, Abreu JR, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, Herrath M von, Quan J, King RS, Robinson WH, Utz PJ, Garren H; BHT-3021 Investigators, Steinman L (2013) Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci Transl Med 5: 191ra82
Schatz DA, Bingley PJ (2001) Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab (Suppl 1): 619–622
Simon MC, Pham MN, Schloot NC (2012) Biomarker und Typ-1-Diabetes. Diabetologe 8(1): 11–17
Staeva TP, Chatenoud L, Insel R, Atkinson MA (2013) Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 62: 9–17
Yi P, Park JS, Melton DA (2013) Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell 153: 747–758
Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309: 2473–2479
Literatur zu Abschn. 3.2
DDG (2012) Deutsche Diabetes-Gesellschaft. Praxisempfehlungen der DDG. Diabetes Stoffwechsel 7 (Suppl 2)
DDG (2011) Deutsche Diabetes-Gesellschaft. S3-Leitlinie und Addendum zur S3-Leitlinie Therapie des Typ-1-Diabetes, Version 1.0; September 2011. http://www.Deutsche-Diabetes-Gesellschaft.de/Leitlinien/evidenzbasierte-leitlinien.html. Zugriff 29 Dez 2013
DCCT (1993) Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. New Engl J Med 329: 683–689
Tucker ME (2013) New DCCT data: HbA1c matters today, tomorrow, and 20 years on. Medscape June 23, 2013. http://www.medscape.com/viewarticle/806768. Zugriff 29 Dez 2013
Literatur zu Abschn. 3.3
DDG, AGPD (2009) Deutsche Diabetes-Gesellschaft. Leitlinie von diabetesDE und AGPD, Arbeitsgemeinschaft Pädiatrische Diabetologie. Haak T, Kellerer M (Hrsg) Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. http://www.diabetes-kinder.de/modularx/include/module/dateimanager/data/leitnie-kinderdiabetologie-2009.pdf. Zugriff 29 Dez 2013
Hanas R, Donaghue K, Klingensmith G, Swift PG (2009) ISPAD Clinical Practice Consensus Guidelines. Pediatr Diabetes Supplement. Vollständige Version: http://www.ispad.org/content/ispad-clinical-practice-consensus-guidelines-2009-compendium. Zugriff 29 Dez 2013
Hürter P, Jastram H-U, Regling B, Toeller M, Lange K, Weber B, Burger W, Haller R (2005) Diabetes bei Kindern: ein Behandlungs- und Schulungsprogramm. Diabetes-Buch für Kinder, 3. Aufl. Kirchheim, Mainz
Hürter P, Kordonouri O, Lange K, Danne T (2007) Kompendium pädiatrische Diabetologie. Springer, Berlin Heidelberg, New York
Lange K, Burger W, Holl R, Hürter P, Saßmann H, von Schütz W, Danne T (2009) Diabetes bei Jugendlichen: ein Schulungsprogramm. 2. Aufl. Kirchheim, Mainz
Literatur zu Abschn. 3.4
AWMF (2010) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Betreuung von Neugeborenen diabetischer Mütter. Leitlinie der Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin, der Deutschen Gesellschaft für Perinatale Medizin, der Deutschen Diabetes-Gesellschaft, Deutschen Gesellschaft für Kinder- und Jugendmedizin, und der Deutschen Gesellschaft für Gynäkologie und Geburts hilfe. http://www.awmf.org/uploads/tx_szleitlinien/024-006_S2k_IDA_Betreuung_von_Neugeborenen_diabetischer_Muetter_05-2010_05-2015_01.pdf. Zugriff 28 Okt 2013
Colstrup M, Mathiesen ER, Damm P, Jensen DM, Ringholm L (2013) Pregnancy in women with type 1 diabetes: Have the goals of St. Vincent declaration been met concerning foetal and neonatal complications? J Matern Fetal Neonatal Med 26(17): 1682–1686
Feig DS, Palda VA (2002) Type 2 diabetes in pregnancy: a growing concern. Lancet 11; 359(9318): 1690–1692
Fuhrmann K, Reiher H, Semmler K, Fischer F, Fischer M. Glockner E (1983) Prevention of congenital malformations in infants of insulin-dependent diabetic mothers. Diabetes Care 6(3): 219–223
Handisurya A, Bancher-Todesca D, Schober E, Klein K, Tobler K, Schneider B, Pollak A, Husslein P, Luger A, Kautzky-Willer A (2012) Risk factor profile and pregnancy outcome in women with type 1 and type 2 diabetes mellitus. J Womens Health (Larchmt) 20(2): 263–271
HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA (2008) Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358(19): 1991–2002
Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington (DC): National Academies Press 2009 http://www.ncbi.nlm.nih.gov/pubmed/20669500. Zugriff 28 Okt 2013
Jensen DM, Korsholm L, Ovesen P, Beck-Nielsen H, Moelsted- Pedersen L, Westergaard JG, Moeller M, Damm P (2009) Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care 32(6): 1046–1048
Kleinwechter H, Bührer C, Hunger-Battefeld W, Kainer F, Kautzky-Willer A, Pawlowski B, Reiher H, Schäfer-Graf U, Sorger M (2012 a) Diabetes und Schwangerschaft. Evidenzbasierte Leitlinie der Deutschen Diabetes- Gesellschaft 2008. http://www.deutsche-diabetesgesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/EBL_Schwangerschaft_2008.pdf. Zugriff 28 Okt 2013
Kleinwechter H, Schäfer-Graf U, Bührer C, Hösli I, Kainer F, Kautzky-Willer A, Pawlowski B, Schunck K, Somville T, Sorger M (2012 b) Diabetes und Schwangerschaft. Diabetol Stoffwechs. 2012;7(S2): S185–S190
Literatur zu Abschn. 3.5
Becker RH, Frick AD, Burger F et al. (2005) Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 113: 435–443
Bliss M (2007) The Discovery of Insulin, 25th edn. University of Chicago Press
Ceriello A et al. (2012) Insulin Lispro protamine suspension in the treatment of patients with type 1 and type diabetes mellitus: a systematic review of published data. Expert Opin. Pharmacother 13(2): 255–281
Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Resaerch Network Epidemiology Group. Diabetologia 52: 1755–1765
Currie CJ, Poole CD, Gale EA et al. (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766–1777
Dahmen R, Bergmann K, Lehmann A, Tillner J, Jax T, Heise T, Becker RHA (2013) New insulin glargine U300 formulation evens and prolongs steady state PK and PD profiles during euglycemic clamp in patients with type 1 diabetes (T1DM). Diabetes 62 (Suppl 1): 920 P
Davidson MB, Raskin P, Tanenberg R et al. (2011) A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocrine Practice 17(3): 395–403
Dideriksen LH, Jorgensen LN, Drejer K (1992) Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 41: 143A
EMA (2013) European Medicines Agency. Outcome of reviewof new safety data on insulin glargine. EMA/329790/2013. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2013/05/WC500143823.pdf Zugriff31 Jan 2014
EMA (Actrapid) http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000424/WC500021658.pdf. Zugriff 31 Jan 2014. Zugriff 31 Jan 2014
EMA (Apidra) http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000557/WC500025250.pdf
EMA (Humalog) http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000088/WC500050332.pdf. Zugriff 31 Jan 2014
EMA (Insuman) http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000201/WC500033784.pdf. Zugriff 31 Jan 2014
EMA (Lantus) http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf. Zugriff 31 Jan 2014
EMA (Levemir) http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000528/WC500036662.pdf. Zugriff 31 Jan 2014
EMA (NovoMix) http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000308/WC500029441.pdf. Zugriff 31 Jan 2014
EMA (NovoRapid) http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000258/WC500030372.pdf. Zugriff 31 Jan 2014
FDA (2013) U.S. FDA. Food and Drug Administration. Information for the physician. Humulin R. Reference ID 3273556. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018780s132lbl.pdf. Zugriff 31 Jan 2014 Garber AJ (2013) Methods to enhance delivery of prandial insulin and basal-prandial insulin. Diabetes Obesity Metabolism 15 (Suppl 1): 11–17
Garber AJ (2013) Will the next generation of basal insulins offer clinical advantages? Diabetes Obesity Metabolism doi;10.1111/dom12291
Gerstein HC et al. (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4): 319–328
Goldman-Levine JD, Patel DK, Schnee DM (2009) Insulin Degludec: A Novel Basal Insulin Analogue. New Drug Devel opments 47: 269–277
Halbron M et al. (2007) Insulintherapy for type 2 diabetes: Premixed or basal-prandial? Diabetes Metab 33: 316–320
Hemkens LG, Grouven U, Bender R et al. (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52: 1732–1744
Holman RR, Thorne KI, Farmer AJ et al. for the 4-T Study Group (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357: 1716–1730
Holman RR, Farmer AJ, Davies MJ et al., 4-T Study Group (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361: 1736–1747
Home PD (2012) The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obesity Metabolism 14: 780–788
Jonasson JM, Ljung R, Talbäck M et al. (2009) Insulin glargine use and short-term indicence of malignancies – a population- based follow-up study in Sweden. Diabetologia 52: 1745–1754
Keating GM (2013) Insulin degludec and insulin degludec/ insulin aspart: a review of their use in the management of diabetes mellitus. Drugs 73: 575–593
Kurtzhals P, Schäffer L, Sørensen A et al. (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999–1005
Lambert K, Holt RIG (2013) The use of insulin analogues in pregnancy. Diabetes Obesity Metabolism 15: 888–900
Melbin LG et al., The ORIGIN Trial Investigators (2013) Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN Trial. European Heart J doi:10.1093/euroheart/eht332
Peyrot M, Barnett A, Meneghini L, Schumm-Draeger P (2012) Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP) Study. Diabetes Obesity Metabolism 14: 1081–1087
Riddle MC , Rosenstock J, Gerich J et al., the Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 26: 3080–3086
Riddle MC, Bolli GM, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD (2013) New insulin glargine formulation: glucose control and hypoglycemia in people with type 2 diabetes using basal and mealtime insulin. Diabetes 62 (Suppl 1): 43-LB
Rosenstock J, Fonseca V, McGill JB et al. (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52: 1971–1973
Steiner DF, Park S-Y, Støy J, Philipson LH, Bell GI (2009) A brief perspective on insulin production. Diabetes Obesity Metabolism 11 (Suppl 4): 189–196
Tibaldi JM (2011) Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. Clin Ther 33(11): 1630–1642
Zinman B (2013) Newer insulin analogs: advances in basal insulin replacement. Diabetes Obesity Metabolism 15(Suppl 1): 6–10
Literatur zu Abschn. 3.6
Bergenstal R, Klonoff D, Garg S, Bode B, Meredith M, Slover R, Ahmann A, Welsh J, Lee S, Kaufmann F (2013) Thresholdbased insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 369: 224–232
Liebl A, Henrichs H, Heinemann L, Freckmann G, Biermann E, Thomas A (2012) Evidenz und Konsens für den klinischen Einsatz von CGM. Diabetes, Stoffwechsel Herz 21: 32–47
Philip M, Battelino T, Atlas E, Kordonouri O, Bratina N, Miller S, Biester T, Stefanija M, Muller I, Nimri R, Danne T (2013) Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 368: 824–833
Literatur zu Abschn. 3.7
Bellin MD, Barton FB, Heitman A, Harmon JV, Kandaswamy R, Balamurugan AN, Sutherland DER, Alejandro R, Hering BJ (2012) Potent Induction Immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 12: 1576–1583
Fiorina P, Folli F, Bertuzzi F, Maffi P, Finzi G, Venturini M, Socci C, Davalli AM, Orsenigo E, Falqui L, Uccella S, La Rosa S, Usellini L, Properzi G, Di Carlo V, Del Maschio A, Capella C, Secchi A (2003) Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 26: 1129–1136
Fiorina P, Venturini M, Folli F, Losio C, Maffi P, Placidi C, La Rosa S, Orsenigo E, Socci C, Capella C, Del Maschio A, Secchi A (2005) Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care 28: 1303–1310
Gerber PA, Pavlicek V, Demartines N, Zuellig R, Pfammatter T, Wüthrich R, Weber M, Spinas GA, Lehmann R (2008) Simultaneous islet–kidney vs pancreas–kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up. Diabetologia 51: 110–119
Gruessner RW, Sutherland DE, Gruessner AC (2004) Mortality assessment for pancreas transplants. Am J Transplant 4: 2018–2026
Lehmann R, Gerber PA (2011) Der nierenkranke Patient mit Typ 1 Diabetes mellitus: Nierentransplantation allein oder mit Insel- oder Pankreastransplantation? (End-stage nephropathy in type 1 diabetes mellitus: kidney transplantation alone or combined with islet or pancreas transplantation?). Therapeutische Umschau 68: 699–706
Lehmann R, Spinas GA, Moritz W, Weber M (2008) Has time come for new goals in human islet transplantation? Am J Transplant 8: 1096–1100
Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jorgensen HV, Matthews DR, Hougaard P, Thorsteinsson B (2004) Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metabolism Res Rev 20: 479–486
Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AM (2002) Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 51: 2148–2157
Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM (2003) Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 290: 2817–2823
Warnock GL, Thompson DM, Meloche RM, Shapiro RJ, Ao Z, Keown P, Johnson JD, Verchere CB, Partovi N, Begg IS, Fung M, Kozak SE, Tong SO, Alghofaili KM, Harris C (2008) A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 86: 1762–1766
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Danne, T. et al. (2014). Typ-1-Diabetes. In: Schatz, H., Pfeiffer, A. (eds) Diabetologie kompakt. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41358-2_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-41358-2_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-41357-5
Online ISBN: 978-3-642-41358-2
eBook Packages: Medicine (German Language)